W
ithin the most common infections caused by Candida spp., vulvovaginal candidiasis (VVC) has been estimated to affect about 75% of all women at least once in their lifetime (1) (2) (3) .
Despite its high incidence, treatment options for VVC are quite limited. The most commonly used drugs are the azoles, with fluconazole the most frequently used one (4) .
In recent years, an increase in Candida resistance to azoles has been reported, especially regarding non-albicans Candida species (5) . The presence of mechanisms of resistance make the treatment of VVC a challenge of growing proportions (6) (7) (8) (9) .
The antifungal activities of antidepressant drugs were first discovered when three patients with chronic VVC were treated with sertraline for premenstrual syndrome and presented no symptoms of candidiasis during the sertraline treatment course (10) . In response to this finding, studies have shown intrinsic activities of these agents against fungi (10) (11) (12) .
Therefore, the main goal of this study was to determine the antimicrobial activity of one selective serotonin reuptake inhibitor drug, fluoxetine, alone and in combination with fluconazole, against different Candida spp. in order to expand the knowledge regarding the possible antifungal activity of this drug.
Fluoxetine HCl was kindly provided by Labesfal (Fresenius Kabi Group, Portugal). The stock solution was prepared following the manufacturer's instructions: fluoxetine was dissolved in sterile demineralized water at room temperature to achieve a stock solution of 5,000 g/ml. Fluconazole (Sigma-Aldrich, Sintra, Portugal) was dissolved in sterile demineralized water to form a stock solution of 512 g/ml. From the stock solutions, 2-fold serial dilutions were prepared.
Twenty-nine Candida spp. were included in this study, corresponding to two American Type Culture Collection strains (C. albicans ATCC 10231 and C. albicans ATCC 90028) and 27 Candida isolates: C. albicans (n ϭ 7), C. guillermondii (n ϭ 2), C. krusei (n ϭ 2), C. sphaerica (n ϭ 1), C. tropicalis (n ϭ 6), C. glabrata (n ϭ 4), C. parapsilosis (n ϭ 4), and C. lipolytica (n ϭ 1).
The isolates were characterized to the species level by using both molecular identification and an API 32C apparatus (bioMérieux, Vercieux, France) and were kept frozen in brain heart infusion broth (Difco Laboratories, Detroit, MI) with 5% glycerol (Sigma-Aldrich, Sintra, Portugal) at Ϫ70°C until testing. After thawing, the yeast cells were subcultured twice in Sabouraud dex- trose agar (Biokar Diagnostics, Beauvais, France) for 24 h at 37°C to assess viability. The fluoxetine and fluconazole MIC values were determined according to a modified CLSI M27-A3 microdilution reference procedure (see Table 1 , below) (13) . Growth inhibition was visually evaluated after 24 and 48 h of incubation at 37°C under aerobic conditions. For fluoxetine, the MIC was defined as the lowest concentration of drug that completely prevented yeast growth. For fluconazole, the MIC corresponded to an approximately 50% inhibition in growth, which was determined spectrophotometrically (13) .
Determination of the minimal lethal concentration (MLC) was carried out according to the methods of Canton et al. (14) . All experiments were performed in duplicate and repeated independently three times.
Drugs combinations were studied by using a two-dimensional checkerboard procedure with the two antifungal agents and 12 Candida strains (see Table 2 , below) (15) . Growth inhibition was visually evaluated after 48 h of incubation at 37°C under aerobic conditions.
The type of interaction between fluoxetine and fluconazole was calculated based on the fractional inhibitory concentration (FIC) and fractional inhibitory index (FIX). Synergistic, indifferent, and antagonist interactions were defined by FIX values of Ͻ0.5, 0.5 to 4, and Ͼ4, respectively (15) . The antifungal effects of fluoxetine against the 29 tested Candida strains are presented in Table 1 . Depending on the tested concentrations, the drug showed a fungistatic or fungicidal activity against all tested strains. In fact, the MIC and MLC values matched for the majority of the strains (19 of the 29 strains tested). Interestingly, different MIC values were obtained for different strains from the same species, especially for C. albicans, C. tropicalis, and C. parapsilosis.
The antifungal activities of fluoxetine were previously reported for C. albicans and non-albicans Candida species (11, 12) . The previously reported MICs range from 50 to 200 g/ml, and these values fall within the range for our results (9.8 to 625 g/ml). The broader range of MICs reported here is probably related to the higher number of strains included.
The checkerboard technique was used to determine the effects of different concentrations of fluoxetine and fluconazole on the growth of 12 Candida strains.
The phenotypic classification of the 12 Candida strains with respect to susceptibility to fluconazole was made using the CLSI M27-S4 criteria specific for each Candida species (Table 2) (16).
Of the 12 strains enrolled in the test, two were susceptible (S) to fluconazole, with MICs ranging from 0.25 to 0.5 g/ml. The five resistant (R) strains presented MICs between 8 and 64 g/ml. The two C. krusei isolates were intrinsically resistant to fluconazole, as expected. Table 3 presents the MICs obtained for the two drugs, both alone and in combination. A synergistic effect was observed for 6 of the 12 tested strains, and 4 of these 6 strains were resistant to fluconazole. An indifferent effect was observed for the remaining 6 strains.
When the drugs were used in combination, the fluconazole MIC for resistance strains decreased up to 64-fold.
The final effect of fluoxetine depends on the susceptibility profile of a given strain to fluconazole, since a synergistic effect was more evident in the fluconazole-resistant strains. Still, a markedly indifferent effect was evident in the susceptible strains. Since the concentrations of these drugs in vaginal fluid have not yet been defined, we cannot assume their potential antifungal effects in vivo. However, considering the common plasma drug concentration of 200 ng/ml for fluoxetine (17) , it appears that these values are much lower than the obtained MICs. However, these drugs undergo extensive plasma protein binding (Ͼ97%), and this would explain such low plasma drug concentrations. In addition, the drugs can reach concentrations 20 to 40 times higher in some tissues or fluids, for example, the cerebrospinal fluid (3). A topical application directly in the vagina can be assumed to be a desirable therapeutic approach, as it would allow direct introduction of drug quantities that can result in high drug concentrations in this milieu.
The results from this study encourage us to consider a future use of fluoxetine in topical formulations for the treatment of VVC, mainly if combined with azole drugs, especially fluconazole.
